Head to Head Analysis: Tempus AI (NASDAQ:TEM) & Nyxoah (NASDAQ:NYXH)

Tempus AI (NASDAQ:TEM) and Nyxoah (NASDAQ:NYXH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Insider & Institutional Ownership

24.2% of Tempus AI shares are owned by institutional investors. 24.3% of Tempus AI shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Tempus AI and Nyxoah, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempus AI	2	3	9	0	2.50
Nyxoah	1	1	2	0	2.25

Tempus AI presently has a consensus target price of $68.54, suggesting a potential upside of 11.26%. Nyxoah has a consensus target price of $7.00, suggesting a potential upside of 293.26%. Given Nyxoah’s higher probable upside, analysts clearly believe Nyxoah is more favorable than Tempus AI.

Profitability

This table compares Tempus AI and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tempus AI	-22.20%	-53.83%	-11.17%
Nyxoah	-543.21%	-163.73%	-80.24%

Risk & Volatility

Tempus AI has a beta of 3.45, indicating that its stock price is 245% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.

Valuation and Earnings

This table compares Tempus AI and Nyxoah”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempus AI	$1.27 billion	8.70	-$245.03 million	($1.72)	-35.81
Nyxoah	$11.33 million	6.09	-$101.92 million	($2.48)	-0.72

Nyxoah has lower revenue, but higher earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Summary

Tempus AI beats Nyxoah on 11 of the 14 factors compared between the two stocks.

About Tempus AI

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.